About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Panel Discussion on Breast Cancer: Promising Drugs and Future Treatments of Metastatic Disease
By
Holy Cross 9th Annual Winter Oncology Symposium
FEATURING
Ena Segota
,
Reshma L. Mahtani
,
Jessica Burgers
,
Maysa Abu-Khalaf
,
Beverly Moy
March 20, 2019
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
27:39
Breast Health Global Initiative
Metastatic Breast Disease: Treatment and Palliative Care
Feat.
A. Eniu
14:37
Cleveland Clinic Taussig Cancer Institute
Hormone Receptor-Postive Advanced Breast Cancer Case 2: Patient with…
Feat.
J. Abraham
30:13
Nico Karssemeijer
Deep Learning Systems for Reading Mammograms and Breast Tomosynthesis
19:43
Northwestern Medicine: Chicago Live
Northwestern Live: Live Case - 47 y/o Female with History of Metasta…
Feat.
D. Mullady,
A. Aadam
19:23
Holy Cross 9th Annual Winter Oncology Symposium
Genetic Testing in Breast and Ovarian Cancer: BRCA1/2 and PARP Inhib…
Feat.
D. Guaqueta
07:43
Dana-Farber Cancer Institute
Study of Abemaciclib for Patients with RB-Positive, Triple Negative …
Feat.
S. Goel
24:33
Holy Cross 9th Annual Winter Oncology Symposium
Therapeutic Strategies in HER2+ Breast Cancer - Pertuzumab, Neratini…
Feat.
B. Moy
12:05
Holy Cross 9th Annual Winter Oncology Symposium
Future Directions in the Targeting of HER2+ Breast Cancer: duration …
Feat.
B. Moy
12:44
Holy Cross 9th Annual Winter Oncology Symposium
Emerging Targets in ER Positive Breast Cancer: CDK4/6 inhibitors, Bc…
Feat.
M. Abu-Khalaf
07:58
Sandra Swain
ASCO 2019 End-of-study Survival Analysis from the Cleopatra Study Sh…
19:29
2019 Scripps MD Anderson's Oncology Update
ASCO Metastatic HER2+ Breast Review: How Long to Treat Is up To Deba…
Feat.
J. Mortimer
18:38
Peter Schmid
Immunotherapy in Metastatic Triple Negative Breast Cancer: IMpassion…
07:23
Dana-Farber Cancer Institute
Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer
Feat.
S. Tolaney
07:40
Dana-Farber Cancer Institute
Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Br…
Feat.
S. Tolaney
13:18
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
Case of a 65 y/o Woman with DCIS Breast Cancer, pN1 Micrometastases …
Feat.
S. Modi,
H. Jacene,
F. Vicini,
H. Rugo
14:20
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
Case of a 35 y/o Woman with Micrometastatic Carcinoma, RCB-II Whose …
Feat.
S. Modi,
H. Jacene,
F. Vicini,
H. Rugo
05:52
Ashley Mathews
PD-L1 Testing in Breast Cancer: What Makes a Breast Cancer Patient E…
14:11
UNC Lineberger Comprehensive Cancer Center
UNC's 2019 ASCO Update on Margetuximab + Chemo vs Trastuzumab v…
Feat.
E. Ray
16:31
Sandra Swain
Firstline Treatment for HER2+ Metastatic Breast Cancer: How HER2-Tar…
13:11
Sandra Swain
HER2+ Metastatic Breast Cancer: Managing Anti-HER2-Targeted Therapy …